Compare CDW & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDW | DVA |
|---|---|---|
| Founded | 1984 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.9B | 14.9B |
| IPO Year | 2013 | 2003 |
| Metric | CDW | DVA |
|---|---|---|
| Price | $135.63 | $178.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $164.88 | $156.75 |
| AVG Volume (30 Days) | ★ 1.5M | 579.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | ★ 1.38 | N/A |
| EPS | 3.97 | ★ 6.86 |
| Revenue | $10,768,600,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $4.08 | $3.85 |
| Revenue Next Year | $4.01 | $3.07 |
| P/E Ratio | $35.13 | ★ $25.46 |
| Revenue Growth | 6.32 | ★ 6.46 |
| 52 Week Low | $97.12 | $101.00 |
| 52 Week High | $166.60 | $247.49 |
| Indicator | CDW | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 42.43 |
| Support Level | $127.04 | $173.99 |
| Resistance Level | $142.19 | $202.63 |
| Average True Range (ATR) | 5.50 | 5.47 |
| MACD | -1.62 | 0.22 |
| Stochastic Oscillator | 1.78 | 19.52 |
CDW Corp is a multi-brand provider of information technology (IT) solutions to businesses, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. The company's offerings range from hardware and software products to integrated IT solutions and services, including on-premise and cloud capabilities across hybrid infrastructure, digital experience, and security. Its reportable segments are Corporate, Small Business, Public, and Other. The Corporate and Small Business segments serve US private sector business customers, while the Public segment consists of government agencies and education and healthcare institutions in the US. The Corporate segment generates the majority of its revenue in the United States.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.